might need to tone it down on the advertising/self promotion - not sure what the TOU says on that...?btw - who's the institutional investor that is accumulating that you point out?
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress